Allele-specific cancer cell killing in vitro and in vivo targeting a single-nucleotide polymorphism in POLR2A

Cancer Gene Therapy

Volumn 16, Issue 6, 2009, Pages 532-538

  Mook, O R F ^a   Baas, F ^a   De Wissel, M B ^a   Fluiter, K ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; RNA POLYMERASE II; SMALL INTERFERING RNA;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE LOCATION; GENE TARGETING; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY LOSS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ALLELES; ANIMALS; CELL LINE, TUMOR; FEMALE; GENE THERAPY; GENOTYPE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICE; MICE, INBRED STRAINS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA INTERFERENCE; RNA POLYMERASE II; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

MUS MUSCULUS;

EID: 66149158407     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.104     Document Type: Article

References (31)

1. Leung RK, Whittaker PA. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 2005; 107: 222-239.
2. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2: 243-247.
3. Zhang Z, Jiang G, Yang F, Wang J. Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells. Cancer Biol Ther 2006; 5: 1481-1486.
4. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811.
5. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
6. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007; 8: 173-184.
7. Aigner A. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol 2007; 76: 9-21.
8. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643-649.
9. Basilion JP, Schievella AR, Burns E, RiouxP, Olson JC, Monia BP et al. Selective killing of cancer cells based on loss of heterozygosity and normal variation in the human genome: a new paradigm for anticancer drug therapy. Mol Pharmacol 1999; 56: 359-369.
10. Fluiter K, Housman D, Ten Asbroek AL, Baas F. Killing cancer by targeting genes that cancer cells have lost: allelespecific inhibition, a novel approach to the treatment of genetic disorders. Cell Mol Life Sci 2003; 60: 834-843.
11. Ten Asbroek AL, Olsen J, Housman D, Baas F, Stanton Jr V. Genetic variation in mRNA coding sequences of highly conserved genes. Physiol Genomics 2001; 5: 113-118.
12. Fluiter K, ten Asbroek AL, van Groenigen M, Nooij M, Aalders MC, Baas F. Tumor genotype-specific growth inhibition in vivo by antisense oligonucleotides against a polymorphic site of the large subunit of human RNA polymerase II. Cancer Res 2002; 62: 2024-2028.
13. Abdelgany A, Wood M, Beeson D. Allele-specific silencing of a pathogenic mutant acetylcholine receptor subunit by RNA interference. Hum Mol Genet 2003; 12: 2637-2644.
14. Ding H, Schwarz DS, Keene A, Affar el B, Fenton L, Xia X et al. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell 2003; 2: 209-217.
15. Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchenio T, Lozano G et al. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 2002; 99: 14849-14854.
16. Miller VM, Gouvion CM, Davidson BL, Paulson HL. Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res 2004; 32: 661-668.
17. Miller VM, Xia H, Marrs GL, Gouvion CM, Lee G, Davidson BL et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 2003; 100: 7195-7200.
18. Du Q, Thonberg H, Wang J, Wahlestedt C, Liang Z. A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res 2005; 33: 1671-1677.
19. Schwarz DS, Ding H, Kennington L, Moore JT, Schelter J, Burchard J et al. Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2006; 2: 1307-1318.
20. ten Asbroek AL, Fluiter K, van Groenigen M, Nooij M, Baas F. Polymorphisms in the large subunit of human RNA polymerase II as target for allele-specific inhibition. Nucleic Acids Res 2000; 28: 1133-1138.
21. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci USA 1984; 81: 1991-1995.
22. Duxbury MS, Matros E, Ito H, Zinner MJ, Ashley SW, Whang EE. Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Ann Surg 2004; 240: 667-674; discussion 675-676.
23. Mook OR, Baas F, de Wissel MB, Fluiter K. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther 2007; 6: 833-843.
24. Meyer T, Regenass U, Fabbro D, Alteri E, Rosel J, Muller M et al. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro antiproliferative as well as in vivo anti-tumor activity. Int J Cancer 1989; 43: 851-856.
25. Kurosawa T, Igarashi S, Nishizawa M, Onodera O. Selective silencing of a mutant transthyretin allele by small interfering RNAs. Biochem Biophys Res Commun 2005; 337: 1012-1018.
26. Dykxhoorn DM, Schlehuber LD, London IM, Lieberman J. Determinants of specific RNA interference-mediated silencing of human beta-globin alleles differing by a single nucleotide polymorphism. Proc Natl Acad Sci USA 2006; 103: 5953-5958.
27. Li Y, Yokota T, Matsumura R, Taira K, Mizusawa H. Sequence-dependent and independent inhibition specific for mutant ataxin-3 by small interfering RNA. Ann Neurol 2004; 56: 124-129.
28. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 2004; 23: 1448-1456.
29. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004; 23: 1539-1548.
30. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005; 65: 967-971.
31. Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn EG et al. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut 2005; 54: 1298-1308.